№ files_lp_3_process_7_040057
File format: docx Character count: 8787 File size: 25 KB
Professional consensus statement issued by the British Gynaecological Cancer Society in January 2019 outlining agreed clinical positions on the application, safety, technical performance and implementation of sentinel lymph node techniques in vulval, cervical and endometrial cancer within UK practice.
Year: 2019
Month: January
Organisation: British Gynaecological Cancer Society (BGCS)
Region: United Kingdom
Field: Gynaecological Oncology
Topic: Sentinel Lymph Node Technique in Vulval, Cervical and Endometrial Cancer
Document Type: Consensus Statement
Authors: Christina Fotopoulou; Thomas Ind; Peter Baldwin; Robin Crawford; Omer Devaja; Stephen Dobbs; Jonathan Frost; Ketan Gajjar; Raji Ganesan; Sonali Kaushik; Jo Morrison; Marielle Nobbenhuis; Nithya Ratnavelu; Phil Rolland; Naveena Singh; Alexandra Taylor; Sudha Sundar; Andy Nordin
Participating Body: BGCS officers and expert members of the UK gynaecological oncological community
Methodology: Delphi process with two rounds and 80% consensus threshold
Scope: Applicability, oncologic safety and surgical safety of sentinel lymph node algorithms
Cancers Addressed: Vulval cancer; Cervical cancer; Endometrial cancer
Guidelines Considered: European Society of Gynaecological Oncologists (ESGO)
Implementation Context: UK gynaecological cancer centres
Clinical Focus: Surgical staging; SLN mapping; Lymphadenectomy; Histological ultra-staging; Training and audit requirements
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
British Gynaecological Cancer Society (BGCS) Tubo-ovarian Cancer Guidelines: Recommendations for Practice Update 2024
Year: 2024
Region / City: United Kingdom
Topic: Gynaecological Oncology
Document Type: Clinical Guidelines
Author: Esther Moss, Alexandra Taylor, Adrian Andreou, Christine Ang, Rupali Arora, Ayoma Attygalle, Mona El-Bahrawy, Susana Banerjee, Rebecca Bowen, Lynn Buckley, Nick Burbos, Sarah Coleridge, Richard Edmondson, Christina Fotopoulou, Jonathan Frost, Raji Ganesan, Angela George, Louise Hanna, Baljeet Kaur, Ranjit Manchanda, Hillary Maxwell, Agnieszka Michael, Tracey Miles, Claire Newton, Shibani Nicum, Nithya Ratnavelu, Neil Ryan, Sudha Sundar, Katherine Vroobel, Axel Walther, Jason Wong, Jo Morrison
Target Audience: Healthcare professionals specializing in gynaecological oncology
Period of Validity: 2024 onwards
Approval Date: Not specified
Modification Date: Not specified
BGCS Travelling Fellowship Application Form 2026
Year: 2026
Organization: British Gynaecological Cancer Society (BGCS)
Type of document: Application form
Target audience: Gynaecological oncology practitioners and trainees
Award categories: Gynaecological Oncology Nurse, Surgical, Non-surgical, Subspecialty Trainee, Clinical/Medical Oncology Trainee
Value of award: £1000
Conditions: Travel within 12 months of award, submission of report within 8 weeks, declaration of other awards
Submission method: Email to Awards Administrator
Required documents: Completed form, two references, CV, BGCS membership confirmation
Evaluation criteria: Structure and clarity, references, value to patients, value to NHS, personal development
Contact: [email protected]
Website: https://www.bgcs.org.uk/members-area/awards-grants-and-prizes/
Purpose of submission for durvalumab and olaparib in the treatment of advanced, metastatic, or recurrent endometrial cancer
Year: 2024
Region / city: Global
Theme: Oncology, Endometrial Cancer, Pharmaceutical Submissions
Document Type: Medical Submission
Organization / Institution: AstraZeneca Pty Ltd
Author: AstraZeneca Pty Ltd
Target Audience: Medical professionals, regulatory bodies, pharmaceutical companies
Period of validity: Not specified
Approval Date: Not specified
Modification Date: Not specified
Public Summary of PBAC Resubmission for Dostarlimab (Jemperli) in Recurrent or Advanced dMMR Endometrial Cancer, November 2022
Year: 2022
Country: Australia
Therapeutic area: Oncology
Disease: Endometrial cancer
Biomarker status: Mismatch repair deficient (dMMR)
Medicine name: Dostarlimab
Brand name: Jemperli
Dosage form: Solution concentrate for intravenous infusion
Sponsor: GlaxoSmithKline Australia Pty Ltd
Regulatory body: Pharmaceutical Benefits Advisory Committee
Submission type: Standard Re-entry submission
Requested listing: Section 100
Comparator treatments: Standard of care chemotherapy; pembrolizumab plus lenvatinib; pembrolizumab monotherapy
Clinical trial referenced: GARNET
Approval status: Provisional approval
Indication: Recurrent or advanced endometrial cancer after platinum-containing regimen
Decision context: PBS listing consideration
Period covered: Up to November 2022
Supplementary Table 1. Characterization of endometrial cancer cell lines.
Year: n.d.
Region / city: n.d.
Topic: Cancer research
Document type: Supplementary table
Organization / institution: n.d.
Author: n.d.
Target audience: Researchers, medical professionals
Effective period: n.d.
Approval date: n.d.
Amendment date: n.d.
APPLICATION FORMESGO Accreditation of Endometrial Cancer Surgery
Year: 2023
Region / City: N/A
Subject: Endometrial Cancer Surgery Accreditation
Document Type: Application Form
Organization / Institution: ESGO
Author: N/A
Target Audience: Medical centers, healthcare professionals
Period of validity: N/A
Approval Date: N/A
Date of changes: N/A
Supplementary Figure Legends of EpCAM and LEF1 Expression in Endometrial Cancer Studies
Year: 2026
Region / City: Not specified
Subject: Molecular and cellular analysis of endometrial cancer
Document Type: Supplementary figures
Institution: Not specified
Authors: Not specified
Target Audience: Researchers in oncology and molecular biology
Study Period: Not specified
Data Sources: Human endometrial cancer patients, cancer cell lines, mouse endometrial tissues, TCGA database
Methods: Immunohistochemistry, immunofluorescence, ChIP-seq, RT-qPCR, AFM
Measured Parameters: Gene expression, cell migration, apoptosis, cytoskeleton content, adhesion force
Statistical Significance Indicators: * P<0.05, ** P<0.01, *** P<0.005, **** P<0.001
Service Specification for Endometrial Biopsy
Year: 2017-2018
Region / city: Doncaster
Subject: Gynaecology, Endometrial Biopsy
Document Type: Service Specification
Organization: NHS Doncaster CCG
Author: Not specified
Target Audience: Healthcare providers, GPs
Effective Period: 1st April 2017 to 31st March 2018
Approval Date: Not specified
Date of Last Review: Annual
Changes Date: Not specified
Topics: Vulval BGCS endometrial